H₂ Global Group’s subsidiary, H₂ Medical Technologies, has received official approval from The State Institute for Drug Control (SÚKL) to initiate a clinical study focused on molecular hydrogen inhalation therapy for patients with mild cognitive impairment (MCI), an early stage of Alzheimer’s disease.
The milestone for Czech and European biotechnology represents Europe’s first fully approved clinical trial investigating non-invasive hydrogen inhalation as a neuroprotective therapy.
The project is based on pioneering research by Shigeo Ohta, co-founder of H₂ Global Group and widely regarded as the founding father of therapeutic hydrogen medicine. Ohta transferred his European patent, titled “Prophylactic or Therapeutic Agent for Dementia,” to the Group.
“Launching a clinical study that directly builds on Professor Ohta’s patent is both an honour and a responsibility,” said Milan Krajíček, co-founder of H₂ Global Group.
“This milestone proves that Czech innovation and research have truly a global relevance.”
“While several antibody-based drugs have been approved to slow Alzheimer’s progression, there is still no widely available, safe, and effective non-invasive treatment,” said David Maršálek, founder and CEO of H₂ Global Group.
“Our goal is to offer patients and physicians a gentle, accessible, and scientifically validated solution.”
The study will begin in January 2026 in cooperation with David Školoudík, one of Czechia’s leading neurologists. The six-month project aims to achieve the world’s first regulatory registration of a medical device utilising molecular hydrogen.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.